Top

Published in:

01-07-2018 | COMMENTARY

A new era for dementia epidemiology: Alzheimer’s disease, hardening of arteries, or just old age?

Author: Lewis H. Kuller

Published in: European Journal of Epidemiology | Issue 7/2018

Excerpt

The paper by Glymour et al. questions the recently published research framework for the diagnosis of Alzheimer’s disease (AD) for research studies [1]. Their interpretation of the role of amyloid in the diagnosis of AD is inaccurate and has led them to a faulty interpretation of the need for these new guidelines [2]. …

Glymour M, Brickman AM, Kivimaki M, Mayeda ER, Chene G, Dufouil C, Manly JJ. Will biomarker-based diagnosis of Alzheimer’s disease maximize scientific progress? Evaluating proposed diagnostic criteria. Eur J Epidemiol. 2018. https://doi.org/10.1007/s10654-018-0418-4.PubMedCrossRef

Jack CR Jr., Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement J Alzheimer’s Assoc. 2018;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018.CrossRef

Ganguli M, Dodge HH, Chen P, Belle S, DeKosky ST. Ten-year incidence of dementia in a rural elderly US community population: the MoVIES project. Neurology. 2000;54(5):1109–16.CrossRefPubMed

Gilsanz P, Mayeda ER, Glymour MM, et al. Female sex, early-onset hypertension, and risk of dementia. Neurology. 2017;89(18):1886–93. https://doi.org/10.1212/WNL.0000000000004602.CrossRefPubMed

Cadar D, Lassale C, Davies H, Llewellyn DJ, Batty GD, Steptoe A. Individual and area-based socioeconomic factors associated with dementia incidence in England: evidence from a 12-year follow-up in the English longitudinal study of ageing. JAMA Psychiatry. 2018. https://doi.org/10.1001/jamapsychiatry.2018.1012.PubMedCrossRefPubMedCentral

Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science. 2006;314(5800):777–81. https://doi.org/10.1126/science.1132814.CrossRefPubMed

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44.CrossRefPubMed

Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the cardiovascular health study. J Am Geriatr Soc. 2004;52(2):195–204.CrossRefPubMed

Lopez OL, McDade E, Riverol M, Becker JT. Evolution of the diagnostic criteria for degenerative and cognitive disorders. Curr Opin Neurol. 2011;24(6):532–41. https://doi.org/10.1097/WCO.0b013e32834cd45b.CrossRefPubMedPubMedCentral

10.

Kuller LH, Lopez OL, Jagust WJ, et al. Determinants of vascular dementia in the cardiovascular health cognition study. Neurology. 2005;64(9):1548–52. https://doi.org/10.1212/01.WNL.0000160115.55756.DE.CrossRefPubMedPubMedCentral

11.

Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197–204. https://doi.org/10.1212/01.wnl.0000271090.28148.24.CrossRefPubMed

12.

Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55(3):306–19. https://doi.org/10.1002/ana.20009.CrossRefPubMed

13.

Silverberg N, Elliott C, Ryan L, Masliah E, Hodes R. NIA commentary on the NIA-AA research framework: towards a biological definition of Alzheimer’s disease. Alzheimer’s Dement J Alzheimer’s Assoc. 2018;14(4):576–8. https://doi.org/10.1016/j.jalz.2018.03.004.CrossRef

14.

Mormino EC, Betensky RA, Hedden T, et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760–7. https://doi.org/10.1212/WNL.0000000000000431.CrossRefPubMedPubMedCentral

15.

Burnham SC, Bourgeat P, Dore V, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol. 2016;15(10):1044–53. https://doi.org/10.1016/S1474-4422(16)30125-9.CrossRefPubMed

16.

Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924–38. https://doi.org/10.1001/jama.2015.4668.CrossRefPubMedPubMedCentral

17.

Stern Y. An approach to studying the neural correlates of reserve. Brain Imaging Behav. 2017;11(2):410–6. https://doi.org/10.1007/s11682-016-9566-x.CrossRefPubMedPubMedCentral

18.

Lopez OL, Becker JT, Chang Y, et al. Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. Neurology. 2018;90(21):e1920–8. https://doi.org/10.1212/WNL.0000000000005549.CrossRefPubMed

19.

Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957–65. https://doi.org/10.1016/S1474-4422(13)70194-7.CrossRefPubMedPubMedCentral

20.

Yang FM, Grigorenko A, Tommet D, et al. AD pathology and cerebral infarctions are associated with memory and executive functioning one and five years before death. J Clin Exp Neuropsychol. 2013;35(1):24–34. https://doi.org/10.1080/13803395.2012.740001.CrossRefPubMed

21.

Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–96. https://doi.org/10.1056/NEJMra023144.CrossRefPubMed

22.

Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004;10(10):1055–63. https://doi.org/10.1038/nm1113.CrossRefPubMed

23.

Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804. https://doi.org/10.1056/NEJMoa1202753.CrossRefPubMedPubMedCentral

24.

Benzinger TL, Blazey T, Jack CR Jr., et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci USA. 2013;110(47):E4502–9. https://doi.org/10.1073/pnas.1317918110.CrossRefPubMed

25.

Donahue JE, Johanson CE. Apolipoprotein E, amyloid-beta, and blood–brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol. 2008;67(4):261–70. https://doi.org/10.1097/NEN.0b013e31816a0dc8.CrossRefPubMed

26.

Kuller LH, Lopez OL. Dementia and Alzheimer’s disease: a new direction. The 2010 Jay L. Foster memorial lecture. Alzheimer’s Dement J Alzheimer’s Assoc. 2011;7(5):540–50. https://doi.org/10.1016/j.jalz.2011.05.901.CrossRef

27.

Jackrel ME, Shorter J. Protein-remodeling factors as potential therapeutics for neurodegenerative disease. Front Neurosci. 2017;11:99. https://doi.org/10.3389/fnins.2017.00099.CrossRefPubMedPubMedCentral

28.

Goudsmit J. The incubation period of Alzheimer’s disease and the timing of tau versus amyloid misfolding and spreading within the brain. Eur J Epidemiol. 2016;31(2):99–105. https://doi.org/10.1007/s10654-016-0144-8.CrossRefPubMedPubMedCentral

29.

Dubnikov T, Cohen E. The emerging roles of early protein folding events in the secretory pathway in the development of neurodegenerative maladies. Front Neurosci. 2017;11:48. https://doi.org/10.3389/fnins.2017.00048.CrossRefPubMedPubMedCentral

30.

Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–20. https://doi.org/10.1016/j.jacc.2016.06.033.CrossRefPubMed

31.

Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94. https://doi.org/10.1093/eurheartj/ehv338.CrossRefPubMed

32.

Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007;13(9):1029–31. https://doi.org/10.1038/nm1635.CrossRefPubMedPubMedCentral

33.

Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR. AD brain pathology: vascular origins? Results from the HAAS autopsy study. Neurobiol Aging. 2008;29(10):1587–90. https://doi.org/10.1016/j.neurobiolaging.2007.03.008.CrossRefPubMed

34.

Gottesman RF, Schneider AL, Zhou Y, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443–50. https://doi.org/10.1001/jama.2017.3090.CrossRefPubMedPubMedCentral

35.

George DR, Whitehouse PJ, D’Alton S, Ballenger J. Through the amyloid gateway. Lancet. 2012;380(9858):1986–7.CrossRefPubMed

36.

Traynor BJ, Rademakers R. Dementia research-A roadmap for the next decade. JAMA Neurol. 2017;74(2):141–2. https://doi.org/10.1001/jamaneurol.2016.5004.CrossRefPubMedPubMedCentral

Title: A new era for dementia epidemiology: Alzheimer’s disease, hardening of arteries, or just old age?
Author: Lewis H. Kuller
Publication date: 01-07-2018
Publisher: Springer Netherlands
Published in: European Journal of Epidemiology / Issue 7/2018
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-018-0420-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A new era for dementia epidemiology: Alzheimer’s disease, hardening of arteries, or just old age?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2018

How accurately is euthanasia reported on death certificates in a country with legal euthanasia: a population-based study

Gestational age at birth and risk of intellectual disability without a common genetic cause

Will biomarker-based diagnosis of Alzheimer’s disease maximize scientific progress? Evaluating proposed diagnostic criteria

Broadening the scope of epidemiologic dementia research

External validation of four dementia prediction models for use in the general community-dwelling population: a comparative analysis from the Rotterdam Study

Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease